15W 18

I hereby this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

on July 17. 2006

Glenn P. Ladwig, Patent Attorney

INFORMATION DISCLOSURE STATEMENT Examining Group 1645 Patent Application Docket No. C&R-103 Serial No. 10/538,195

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner

(Not yet assigned)

Art Unit

1645

Applicants

Carmit Levita, Richard Joseph Fagan, David Michalovich, Melanie Yorke

Serial No.

10/538,195

Filed

June 9, 2005

For

Midkine-Like Protein

MS AMENDMENT Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §§1.97 AND 1.98

Sir:

The patent application referred to above was filed in the U.S. Patent Office as a national application under 35 U.S.C. §371. The applicants have been notified that a copy of the International Search Report has been made available in the national stage file as indicated on the Notification of Acceptance of the Application under 35 U.S.C. §371 (Form PCT/DO/EO/903). The Notification does not indicate whether copies of the references cited in the International Search Report were received by the Patent Office. Therefore, copies of the references cited in the International Search Report are enclosed for the Examiner's convenience. However, the applicants have not submitted a copy of the U.S. patent cited on attached Form PTO/SB/08 pursuant to 37 C.F.R. §1.98(a)(2)(ii). In accordance with 37 C.F.R. §1.56, the applicants hereby request that the references cited in the

Docket No. C&R-103 Serial No. 10/538,195

2

International Search Report and listed on the attached form PTO/SB/08 be made of record and considered in the examination of the subject application.

The applicants respectfully assert that the substantive provisions of 37 C.F.R. §§1.97 and 1.98 are met by the foregoing statement.

Respectfully submitted,

Glenn P. Ladwig
Patent Attorney

Registration No. 46,853

Phone No.:

352-375-8100

Fax No.:

352-372-5800

Address: P.O. Box 142950

Gainesville, FL 32614-2950

GPL/mv

Attachments: Form PTO/SB/08 (2 pages); copies of some cited references

PTO/SB/08A (08-03) Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | Substitute for form 1449A/PTO | | | | Complete if Known | | |
|---|-----------------------------------|-----------|----|-----|------------------------|---------------|--|
| | | | | UDE | Application Number | 10/538,195 | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT | | | | | Filing Date | June 9, 2005 | |
| | SIAIENE | ENIBYAPPI | | ANI | First Named Inventor | Carmit Levita | |
| | (use as many sheets as necessary) | | | | Art Unit | 1645 | |
| | | | | | Examiner Name | | |
| | Sheet | 1 | of | 2 | Attorney Docket Number | C&R-103 | |

| U.S. PATENT DOCUMENTS | | | | | | |
|-----------------------|---------------|--|--------------------------------|---|---|--|
| Examiner Initials* | Cite No. 1 | Document Number Number - Kind Code ² (if known) | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | |
| | U1 | US-6,083,907 | 07-04-2000 | Uchida et al. | All | |
| | U | US- | <u> </u> | | | |
| | Ų | US- | | | | |
| | Ú | US- | | | | |
| | U | US- | | | | |
| | U | US- | | | | |
| | U | US- | | | | |
| | U | US- | | | | |
| | U | US- | | | | |

| FOREIGN PATENT DOCUMENTS | | | | | | |
|--------------------------|--------------------------|---|--------------------------------|--|---|----------|
| ···· | | Foreign Patent Document | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T⁴ |
| Examiner Initials* | Cite No. ¹ | Country Code ³ - Number ⁴ - Kind Code ⁵ (if known) | | | | |
| | F1 | EP 0 476 233 A1 | 03-25-1992 | American Cyanamid Co. | All | |
| | F2 | WO 01/36635 A2 | 05-25-2001 | Curagen Corp. | All | <u> </u> |
| | F | | | | | |
| | F | | | | | |
| 0 0 | F | | | | | |
| | F | | | | | |
| | F | | | | | |

| Examiner | Da | te |
|-----------|----|----------|
| Signature | Co | nsidered |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. See Kind Codes of USPTO Patent Documents, by the two-letter code (WPO Standard T.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language. Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the

Sheet

PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

ction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

of

| Complete if Known | | | |
|------------------------|---------------|--|--|
| Application Number | 10/538,195 | | |
| Filing Date | June 9, 2005 | | |
| First Named Inventor | Carmit Levita | | |
| Group Art Unit | 1645 | | |
| Examiner Name | | | |
| Attorney Docket Number | C&R-103 | | |

| NON PATENT LITERATURE DOCUMENTS | | | | | | |
|---------------------------------|--------------------------|--|----|--|--|--|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T² | | | |
| | R1 | AKHTER, S. et al. "Clusters of basic amino acids in midkine: roles in neurite-promoting activity and plasminogen activator-enhancing activity" J. Biochem., 1998, 123:1127-1136. | | | | |
| | R2 | BERNARD-PIERROT, E. et al. "Dominant negative effectors of heparin affin regulatory peptide (HARP) angiogenic and transforming activities" J. Biol. Chem., 2002, 277:32071-32077. | | | | |
| | R3 | IKEDA, S. et al. "cDNA cloning of bovine midkine and production of the recombinant protein, which affects in vitro maturation of bovine oocytes" <i>Mol. Reprod. Dev.</i> , 2000, 57:99-107, sequence information—database accession no. Q9N0E6. | | | | |
| | R | | | | | |
| | R | | | | | |
| | R | · | | | | |
| | R | | | | | |
| | R | | | | | |
| | R | | | | | |
| | R | | | | | |
| | R | | | | | |
| | R | | | | | |
| | R | | | | | |

| Examiner | Date | |
|-----------|-----------|---|
| Signature | Considere | d |

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance

and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including the complete that the public translation is the USPTO. The will have depending upon the individual case. Any comments on the gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.